/Companies

Montis Biosciences

Leuven, BE · Founded 2020 · 15 employees on LinkedIn · 6 known investors

Find your way into Montis Biosciences

Sign up to find every way you can get introduced to Montis Biosciences

  • Your email: who you already know at Montis Biosciences, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Montis Biosciences team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Montis Biosciences develops anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome and a second CD93 program in lung squamous cell carcinoma. The biotech company is based near Leuven, Belgium.

Founders & leadership

FGFederico Grossi
Federico GrossiClinical Advisor & Acting CMO

Investors · 6

Funding

SEC filings, press & company announcements
  • Undisclosed amountseed financingFeb 2020
    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Founder mafia

2 people who came through Montis Biosciences went on to found or lead other companies.

Frequently asked questions

What does Montis Biosciences do?
Montis Biosciences develops anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome and a second CD93 program in lung squamous cell carcinoma. The biotech company is based near Leuven, Belgium.
Who are Montis Biosciences's investors?
Montis Biosciences's investors include Droia Ventures, ALSA Ventures, Pfizer Ventures, VIB, Pfizer Venture Investments, Polaris Partners.
Where is Montis Biosciences headquartered?
Montis Biosciences is headquartered in Leuven, BE.